Cronos Group Inc. (CRON)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.9600 |
| Open | 1.9300 |
| Bid | 1.9600 x 27000 |
| Ask | 1.9700 x 1800 |
| Day's Range | 1.9000 - 1.9800 |
| 52 Week Range | 1.6400 - 3.6160 |
| Volume | |
| Avg. Volume | 2,752,804 |
| Market Cap | 754.073M |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3800 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.55 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CRON
Related Research
- Cronos Group Inc. Common ShareAnalyst Report: Cronos Group Inc.Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.RatingFair ValueEconomic Moat26 days agoMorningstar
InvestorPlaceHidden Gems: 3 Cannabis Stocks Flying Under the Radar
Cannabis stocks have navigated an extended period of uncertainty and financial depression thanks to regulatory headwinds. Further, most cannabis companies have witnessed an extended period of cash burn. There is, however, some optimism and I believe that these overlooked cannabis stocks to buy should be considered. The good news is that even without federal level legalization, the cannabis market in the U.S. is likely to be worth $71 billion by 2030. If we consider the European markets, the tota
ZacksCalliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?
Calliditas Therapeutics AB Sponsored ADR (CALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
InvestorPlace3 Penny Stocks That Can Still Double Before the End of 2023
The market year-to-date has been rewarding after the big correction witnessed last year. There are several growth and penny stocks that have bounced back strongly after being decimated last year. While some stocks trade at fair value or are overvalued, there are penny stocks to buy that trade at a valuation gap. This column focuses on the non-speculative penny stocks to buy for 100% returns in the next few months. Of course, the rally depends on a few specific catalysts. If these factors play ou
